ImmunoPrecise Antibodies Ltd. (HYFT) AI Stock Analysis
HYFT AI stock analysis summary
AI ResearchMindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (NASDAQ: HYFT), is a bio-native AI company developing biologics and AI drug discovery platforms. Annual revenue declined 37.5% in FY2026 to $15.3M with net income of -$13.7M. The company ended the July 31, 2026 quarter with $7.6M in cash and short-term investments.
- Market cap
- $61.7M
- Revenue (TTM)
- $16.2M
- P/E
- —
- 1Y return
- -20.1% S&P 500 16.8%
- Avg. target
- $4.33 230.8% vs last close
Bull case
- Quarterly revenue grew 21.3% year-over-year for the period ended July 31, 2026.
- All 3 covering analysts rate the company a Strong Buy, with a mean price target of $4.33.
- Gross margin expanded to 58.8% in FY2026, up from 55.3% in FY2025.
Bear case
- Annual revenue fell 37.5% in FY2026, driving a 5-year revenue CAGR of -3.1%.
- The company posted negative free cash flow of -$12.7M in FY2026 with net income of -$13.7M.
- Shareholder dilution has been substantial, with share count increasing 142.0% over 5 years.
What ImmunoPrecise Antibodies does
MindWalk Holdings Corp. operates as a bio-native AI company headquartered in Austin, Texas. Incorporated in 1983 and previously known as ImmunoPrecise Antibodies Ltd., the company changed its name to MindWalk Holdings Corp. in September 2025. It discovers and develops biologics utilizing HYFT Technology and its LensAI platform. The company also advances artificial intelligence drug discovery and biologics using ReefIQ technology, operating with 74 employees.
Growth and profitability
Over the past five fiscal years, revenue contracted at a 5-year CAGR of -3.1%, dropping from $24.5M in FY2025 to $15.3M in FY2026. Gross margin rose to 58.8% in FY2026 from 55.3% in FY2025, while operating margin was -96.0%. Net income remained negative across all five years, finishing at -$13.7M in FY2026 compared to -$30.2M in FY2025. Diluted EPS stood at -$0.26 in FY2026. For the trailing twelve months ended July 31, 2026, revenue was $16.2M with quarterly revenue growth of 21.3% year-over-year, while trailing twelve month operating margin was -159.9%.
Balance sheet and cash flow
As of July 31, 2026, the company held $7.6M in cash and short-term investments alongside total debt of $3.5M, leaving net cash at $4.1M. Shareholders' equity was $6.9M against total assets of $17.3M. The current ratio stood at 1.84, and the debt-to-equity ratio was 0.50. Free cash flow was -$12.7M in FY2026, which included capital expenditures of $391,896. Meanwhile, the five-year share count increased by 142.0%.
Valuation and performance
HYFT trades at a price-to-sales multiple of 3.8x and an enterprise value to revenue multiple of 5.7x, based on a market cap of $61.7M and enterprise value of $66.8M. Its price-to-sales multiple is slightly below the 4.1x median of its US-listed Healthcare peers. The company has a price-to-book ratio of 14.0x. Over the past year, the stock declined 20.1% while the S&P 500 rose 16.8%. Over five years, the stock dropped 80.1% versus an 83.0% gain for the benchmark.
What analysts expect
Wall Street coverage includes 3 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The mean price target is $4.33, representing a 230.8% premium over the last close of $1.31 on October 16, 2026. For the fiscal year ending April 30, 2027, consensus estimates project revenue of $17.6M and an EPS of -$0.29. HYFT recorded 0 EPS beats over the last 4 quarters.
Key risks and what to watch
- Operating cash burn remains high with operating cash flow at -$12.3M against $7.6M in total cash and short-term investments.
- The stock has lagged broader benchmarks significantly, delivering a 5-year return of -80.1%.
- Consensus earnings remain in negative territory, with EPS estimated at -$0.29 for the current fiscal year ending April 30, 2027.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this HYFT AI stock analysis
This page is an AI-written research summary of ImmunoPrecise Antibodies Ltd. (HYFT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: HYFT income statement, HYFT balance sheet, HYFT key metrics, HYFT analyst forecast, HYFT chart. See the HYFT stock overview for the latest quote and news.
HYFT AI stock analysis FAQ
What platforms and technologies does MindWalk Holdings Corp. operate?
MindWalk Holdings Corp. uses HYFT Technology and its LensAI platform to discover and develop biologics. It also utilizes ReefIQ technology for AI drug discovery and biologics development.
Does HYFT pay a dividend?
HYFT does not pay a dividend. The company directs available capital toward its operations and reported capital expenditures of $391,896 in FY2026.
What is the consensus analyst target for HYFT stock?
Analysts maintain a mean price target of $4.33 across 3 Strong Buy recommendations, which is 230.8% above its last close of $1.31.
How much debt and cash does HYFT hold?
As of July 31, 2026, HYFT had $7.6M in cash and short-term investments and $3.5M in total debt, resulting in net cash of $4.1M.